Safety Data on Emerging Treatment of Narcolepsy


Experts in sleep medicine summarize the available safety data on various agents for the treatment of narcolepsy.

This is a video synopsis/summary of a panel discussion involving Michael Thorpy, MD; Karl Doghramji, MD, FAASM, DFAPA; Clete Kushida, MD, PhD; and Richard K Bogan, MD.

The discussion focused on the use of oxybate medications in treating narcolepsy. Oxybate comes in different forms, including sodium oxybate immediate release and low sodium oxybate preparations. The immediate-release form is rapidly absorbed and metabolized, requiring 2 doses typically 2 and a half to 4 hours apart before bedtime. Patients are usually started on a low dose and gradually increased. Side effects may include headache, dizziness, nausea, anxiety, and sedation.

The low sodium oxybate preparation has lower sodium content and is preferred by many patients due to reduced side effects related to sodium intake. However, some patients with conditions like orthostatic hypotension or postural orthostatic tachycardia syndrome (POTS) may benefit from the sodium form.

The once-nightly oxybate preparation is a powder with a microencapsulated formulation, providing a fixed dose that is titrated based on the patient's needs. This formulation is preferred by younger patients who object to waking up in the middle of the night to take medication.

Dosing of oxybate is individualized based on various factors, including sleep latency, duration of effect, and side effects. Immediate-release preparations offer more customizable dosing due to their nonlinear pharmacokinetics.

In treating narcolepsy, oxybate is particularly effective in managing cataplexy and improving sleep stability, leading to better daytime alertness and quality of life. Approximately 80% of patients with cataplexy benefit from oxybate treatment.

In conclusion, oxybate medications are valuable treatment options for narcolepsy, with different formulations available to suit individual patient needs. Treatment decisions should be tailored based on the patient's symptoms, preferences, and response to therapy.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.

Related Videos
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
© 2024 MJH Life Sciences

All rights reserved.